All Posts Tagged With: "NVS"
(JNJ) Healthcare Reform: Bad News for Big Pharma?
Healthcare reform could be a minefield for Big Pharma in the long run.
The Patient Protection and Affordable Care Act – less fondly known as “Obamacare” – was the big story to close out the month of March, as the Supreme Court officially took the case.
In...
(HGSI) Human Genome Sciences Analyst Still Neutral on Shares
We are maintaining our Neutral recommendation on Human Genome Sciences Inc. (HGSI) with a target price of $8.25.
Human Genome, founded in 1992 and based in Rockville, Maryland, is a biopharmaceutical...
(BIIB) Biogen Analyst Neutral on Shares
We recently reiterated our Neutral recommendation on Biogen Idec (BIIB). Biogen is the market leader in therapies for the treatment of multiple sclerosis (MS). We believe the company will continue to retain...
(NVS) Novartis’ Cancer Drug Afinitor Shows Promise for Breast Cancer
Novartis’ (NVS) cancer drug Afinitor took a significant step forward, as the company once again presented encouraging data from late-stage trials of Afinitor for the treatment of breast cancer, an indication...
(EU) Emerging Markets: The Way Forward
According to Irish orator, philosopher, & politician Edmund Burke, change is the most powerful law of nature. The winds of change seem to be sweeping across the pharmaceutical industry as well.
Until recently, most commercialization efforts were focused on the U.S....
(MYL) Mylan Earns FDA Approval
Generic maker, Mylan Inc. (MYL) recently announced that its Indian subsidiary Mylan Laboratories has received tentative approval from the US Food & Drug Administration (FDA) for a fixed-dose combination...
(ALNY) Alnylam Pharmaceuticals Completes Trial Enrollment
Alnylam Pharmaceuticals Inc. (ALNY) recently announced it has completed enrollment in a mid-stage study of its pipeline candidate ALN-RSV01, an RNA interference technology (RNAi) therapeutic being studied...
(MYL) Mylan Approved for Zinecard Generic
Mylan, Inc.’s (MYL) generic business was boosted further with the approval from the U.S. Food and Drug Administration (FDA) for its generic version of Pharmacia & Upjohn’s Zinecard injection. Zinecard...
(NVS) Novartis’ Rasitrio Cleared in European Union
Novartis (NVS) recently announced that its triple combination hypertension pill Rasitrio has been cleared in the European Union (EU). Rasitrio combines the currently marketed hypertension pill Razilez (marketed...
(MYL) Mylan Settles with Novartis
Mylan, Inc. (MYL) recently announced a settlement agreement with Novartis (NVS) relating to the generic version of Novartis’ bioidentical...
(ALNY) Alnylam Pharmaceuticals Reveals ALNTTR01 Trial Data
Alnylam Pharmaceuticals Inc. (ALNY) recently presented data from an early stage study of its pipeline candidate ALN-TTR01 at a scientific conference in Japan. ALN-TTR01 is a systemically delivered RNA interference...
(MNTA) Momenta Pharmaceuticals and Novartis AG Sue Watson Pharmaceuticals
Momenta Pharmaceuticals, Inc. (MNTA) and Novartis AG (NVS) filed a lawsuit against Amphastar Pharmaceuticals, Inc. and Watson Pharmaceuticals...
(MYL) Mylan Settles with Roche for Xeloda
Mylan Inc. (MYL) recently announced that it has entered into a settlement and license agreement with Roche (RHHBY) bringing an end to its ongoing litigation with the latter relating to Roche’s...
(NVS) Novartis Drug Cleared in European Union for SEGA
Novartis (NVS) recently received a boost when its drug Votubia was approved for the treatment of subependymal giant cell astrocytomas (SEGA), a benign brain tumor associated with tuberous sclerosis (TS) in...
(NVS) Novartis Neuroendocrine Tumors Drug Cleared in European Union
Novartis’(NVS) drug Afinitor was recently approved in the European Union (EU) for the treatment of patients with advanced neuroendocrine tumors (NET) of pancreatic origin with progressive disease. The drug...
(TEVA) Teva Pharmaceutical Industries Earns Favorable Court Ruling
Teva Pharmaceutical Industries Ltd. (TEVA) recently received a boost with the US District Court for the Southern District of New York issuing a favorable ruling related to the company’s patent infringement...
(ALNY) Alnylam Pharmaceuticals Analyst Maintains Neutral Rating on Shares
We have maintained a Neutral rating on Alnylam Pharmaceuticals, Inc (ALNY) with a target price of $7.00 per share.
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutics...
(MYL) Mylan Analyst Reaffirms Shares at Neutral
We have maintained our Neutral recommendation on Mylan Inc. (MYL) with a target price of $19.00 following an appraisal of second quarter 2011 financial results.
Mylan’s second quarter 2011 earnings...
(HGSI) Human Genome Sciences Analyst Maintains Neutral Recommendation
We are maintaining our Neutral recommendation on Human Genome Sciences Inc. (HGSI) with a target price of $16.00.
Human Genome, founded in 1992 and based in Rockville, Maryland, is a biopharmaceutical...
(MYL) Mylan and Endo Pharmaceuticals in Legal Tussle
Mylan Inc. (MYL) recently announced that Endo Pharmaceuticals (ENDP) filed a patent infringement lawsuit in connection with an abbreviated...
(MYL) Mylan Beats Second Quarter Earnings on All Fronts
Mylan Inc.’s (MYL) second quarter 2011 earnings (excluding special items) of 52 cents per share were above the Zacks Consensus Estimate of 45 cents as well as the year-ago earnings of 37 cents per share....
(AIXG) Company News for July 20, 2011 – Corporate Summary
• Coca-Cola Company (NYSE:KO) reported Q2 EPS of $1.20, ahead of the Zacks Consensus Estimate of $1.16 per share. Revenues for the quarter rose 47% year-over-year to $12.7 billion, beating the Zacks Consensus Estimate...
(AAPL) 2011 Second Quarter Earnings Preview – Detailed
Earnings Preview 7/15/11
Second quarter earnings season is now under way, but things really start to move into high gear next week. There will be 348 firms reporting, and 108 of those are...
(RDY) Dr. Reddy’s Laboratories Earns FDA Approval for Generic
Dr. Reddy’s Laboratories (RDY) delivered yet another positive momentum within a week, as the US Food and Drug Administration (FDA) approved fondaparinux sodium injection, the company’s bioequivalent generic...
(MYL) Mylan Gets HIV Rights from Gilead
Mylan, Inc. (MYL) recently announced that its Indian subsidiary Matrix Laboratories has been granted future rights to produce and sell generic versions of three investigational HIV therapies of Gilead...
(NVS) Novartis Presents Afinitor Data
Recently, Novartis (NVS) presented data from a late-stage study (EXIST-1) of its cancer drug Afinitor (everolimus). The randomized, placebo-controlled, double-blind, multicenter study evaluated the safety...
(NVS) Novartis AG’s Lung Drug Cleared in US
Novartis AG (NVS) recently announced that its once-daily long-acting beta2-agonist (LABA) Arcapta Neohaler (75 mcg) was cleared by the US Food and Drug Administration (FDA) for the long-term...
(WPI) Watson Pharmaceuticals Entangled in Legal Dispute
The legal tussle between Watson Pharmaceuticals Inc. (WPI) and Shire plc (SHPGY) intensified, with the latter filing a patent infringement...
(NVS) Novartis AG’s Afinitor Impresses Again
It seems Novartis AG’s (NVS) breast cancer drug, Afinitor (everolimus), is getting into a habit of delivering positive news. Right after the Committee for Medicinal Products for Human Use (CHMP) of the European...
(SHPGY) Shire Entangled in Legal Dispute
The legal tussle between Shire (SHPGY), Sandoz, Inc. — the generic arm of Novartis (NVS) and Amneal Pharmaceuticals — intensified...